A diabetes drug agreement inked earlier this year between Eli Lilly and Co. and Boehringer Ingelheim GmbH has become a source of dispute in Lilly's so-far-lucrative nine-year partnership with Amylin Pharmaceuticals Inc. for glucagon-like peptide 1 (GLP-1) receptor agonist Byetta (exenatide).